HBW Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Tom Gallen

Managing Editor – Europe

Having joined OTC bulletin as a business reporter in 2013, Tom is currently the managing editor and has an intimate knowledge of the global consumer healthcare market, particularly commercial and regulatory issues. He specializes in analyzing the strategies of the world's leading consumer healthcare companies, their business performance, plans and product portfolios.
Set Alert for Articles By Tom Gallen

Latest From Tom Gallen

Bayer Hit With Fine For Ads Targeting Kids In Hungary

Bayer broke rules on advertising directly to children in promotions for its Supradyn supplement, according to Hungary's competition authority, which imposed a fine on the company for the second time in 12 months. 
Ad Complaints Legal Issues

GSK Launches OTC Fluticasone In Japan Following Switch

GSK has launched Flunase in Japan following the switch of fluticasone propionate. JSMI’s Toshi Tominaga gives his assessment of the product’s prospects as an OTC drug.

Japan Prescription To Otc Switch

Stada’s Acquisition Spree Continues With Deal For Ukrainian Probiotics Player

Germany's Stada will gain a range of probiotics and other OTC brands through the acquisition of Ukraine's Biopharma. The deal is Stada's third in the space of just one month. 
Ukraine Deals

Sore Throat Drugs Heading Behind The Counter In France Over Safety Fears

France's drugs agency wants to restrict sales of OTC sore throat treatments marketed by Sanofi and others to behind the pharmacy counter due to fears of potential adverse events.
France Drug Safety

Australia Suspends 23 Ranitdine Products Contaminated with NDMA

A six-month suspension from sale has been handed to 23 ranitidine drugs sold in Australia. The country's regulator has suggested all 23 are facing a permanent ban over patient safety fears.

Drug Safety Enforcement

Risk Vs Reward: Understanding The Africa Growth Opportunity

Africa represents a new frontier for health and beauty firms. With significant economic growth and a population explosion forecast for the continent, now is the perfect time to start thinking about the Africa opportunity, market expert Ben Longman told the recent Ceuta International Conference.

Middle East and Africa Market Intelligence
See All